Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/34286
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3041]
Metadata
Show full item record
ALTERATIONS IN EVOKED OTOACOUSTIC EMISSIONS BY THE USE OF MEGLUMINE ANTIMONIATE IN AMERICAN TEGUMENTARY LEISHMANIASIS PATIENTS
Author
Bezerra, Débora Cristina de Oliveira
Barcelos, Renata Oliveira de
Castro, Ellen Carvalho de
Duarte, Claudia Cristina Jardim
Oliveira, Raquel de Vasconcellos Carvalhaes
Torraca, Tania Salgado de Sousa
Araújo-Melo, Maria Helena de
Braga, Frederico Pereira Bom
Terceiro, Benivaldo Ramos Ferreira
Paes, Lúcia Regina do Nascimento Brahim
Schubach, Armando de Oliveira
Valete-Rosalino, Cláudia Maria
Barcelos, Renata Oliveira de
Castro, Ellen Carvalho de
Duarte, Claudia Cristina Jardim
Oliveira, Raquel de Vasconcellos Carvalhaes
Torraca, Tania Salgado de Sousa
Araújo-Melo, Maria Helena de
Braga, Frederico Pereira Bom
Terceiro, Benivaldo Ramos Ferreira
Paes, Lúcia Regina do Nascimento Brahim
Schubach, Armando de Oliveira
Valete-Rosalino, Cláudia Maria
Affilliation
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Federal University of Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology and Ophthalmology. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Federal University of Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology and Ophthalmology. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Federal University of Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology and Ophthalmology. Rio de Janeiro, RJ, Brazil.
Federal University of the State of the Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Brazilian National Council for Scientific and Technological Development. Brasilia, DF, Brazil / Carlos Chagas Filho Foundation for Research Support of the state of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Federal University of Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology and Ophthalmology. Rio de Janeiro, RJ, Brazil / Carlos Chagas Filho Foundation for Research Support of the state of Rio de Janeiro. Rio de Janeiro, RJ, Brazil / New University of Lisbon. Hygiene and Tropical Medicine Institute. Lisbon, Portugal.
Federal University of Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology and Ophthalmology. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Federal University of Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology and Ophthalmology. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Federal University of Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology and Ophthalmology. Rio de Janeiro, RJ, Brazil.
Federal University of the State of the Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Brazilian National Council for Scientific and Technological Development. Brasilia, DF, Brazil / Carlos Chagas Filho Foundation for Research Support of the state of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / Federal University of Rio de Janeiro. Faculty of Medicine. Department of Otorhinolaryngology and Ophthalmology. Rio de Janeiro, RJ, Brazil / Carlos Chagas Filho Foundation for Research Support of the state of Rio de Janeiro. Rio de Janeiro, RJ, Brazil / New University of Lisbon. Hygiene and Tropical Medicine Institute. Lisbon, Portugal.
Abstract
Tegumentary Leishmaniasis (TL) is a neglected, non-contagious, infectious disease, caused by different protozoa species of the Leishmania genus that affects skin and mucous membranes. Meglumine Antimoniate (MA), the first drug of choice for TL treatment in Brazil, has already been associated with cochlear toxicity, which is defined as damages of the cochlea caused by exposure to chemical substances, resulting in reversible or irreversible hearing loss. Auditory monitoring for cochlear toxicity aims at the early detection of auditory disorders, enabling, when possible, hearing to be preserved or an early auditory rehabilitation. Although otoacoustic emissions (OAEs) are used in this monitoring, there is no consensus on the criteria that define cochlear toxicity by this examination. The objective of this study was to describe the characteristics of the OAEs in cochlear toxicity monitoring in TL patients using MA.
Share